CTRI/2024/01/062148招募中3 期
A Multicentric, Randomized, Double Blind, Parallel Group, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of FDC of Gabapentin SR plus Methylcobalamin plus Nortriptyline film-coated bilayered tablets Versus FDC of Gabapentin SR Plus Methylcobalamin film-coated tablets in patients with peripheral neuropathic pain with coexistent Vitamin B12 deficiency. - NI
Ravenbhel Healthcare Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The study aims to evaluate patients aged 18-75 with neuropathic pain, Gabapentin and Methylcobalamin treatment, decreased Vitamin B12 levels, and non-specific symptoms like allodynia, burning, shooting, or hyperalgesia.
- •Participants must sign an informed consent document and adhere to all protocol procedures.
排除标准
- •Suspected hypersensitivity to either of the study medications or any of the ingredients of the formulation.
- •Patients using gabapentin for any other neurologic disorders unrelated to peripheral neuropathic pain.
- •Patient taking any other medication for the treatment of peripheral neuropathic pain last two weeks.
- •Patients with a diagnosis of type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) >11%.
- •Patients with abnormal eGFR ( <60 mL/min/1.73 m2).
- •Patients with clinically significant impaired hepatic function. [SGOT & SGPT more than 2.5X the UNL and/or Total bilirubin more than 1.5X the UNL].
- •Any abnormality on 12-lead ECG at screening that in the opinion of the investigator is clinically significant and is judged as potential risk for patient’s participation in the study.
- •Ongoing administration of Monoamine Oxidase (MAO) inhibitors.
- •Patients with medical history of Oncological Conditions.
- •Patients who, in the opinion of the investigator, have history of clinically significant cardiovascular disease (e.g. MI), central nervous system disorders (e.g. seizure, bipolar disorder, generalized anxiety disorder, untreated depression, psychosis or post-traumatic stress disorder), suicidal behavior, angle closure glaucoma, angioedema, urinary retention, thyroid disorder, uncontrolled hypertension.
- •Patients with known cases of HIV, Hepatitis B & C.
- •Participant has a clinically significant disorder that, in the opinion of the investigator, would result in the participant’s inability to understand and comply with the requirements of the study.
- •Female subjects of childbearing potential not be willing to use an acceptable method of contraception.
- •Pregnant woman or lactating mother.
- •Patients participated in any type of clinical study within the last 3 months of the screening date.
- •Patients with known alcohol abuse within last one year and dependency on narcotics, opioids, or any other addictive substances.
- •Patients with an inability to comply with the protocol requirements.
研究者
相似试验
尚未招募
3 期
A Study of Combination of Efonidipine Hydrochloride Ethanolate 20 mg/20 mg and Metoprolol Succinate ER 25 mg/ 50 mg Tablets Versus Efonidipine Hydrochloride Ethanolate Tablets 20 mg and Metoprolol Succinate ER Tablets 50 mg Monotherapy for the treatment of Hypertension.CTRI/2018/12/016625Ajanta Pharma Ltd
尚未招募
3 期
A Study Metoprolol Succinate plus Cilnidipine plus Telmisartan Tablets in patients for treatment of uncontrolled essential hypertension with stable ischemic heart diseaseCTRI/2018/10/016182Ajanta Pharma Ltd
尚未招募
3 期
A clinical study to evaluate efficacy, safety and tolerability of Ripasudil 0.4% plus Timolol Maleate 0.5% vs Ripasudil 0.4% and Timolol Maleate 0.5% monotherapy for the treatment of open angle glaucomaCTRI/2022/01/039211Ajanta Pharma Limited
已完成
3 期
A Study of Combination of Azilsartan Medoxomil plus Cilnidipine Tablets for the treatment of subjects with Hypertension.CTRI/2019/07/020204Synokem Pharmaceuticals Ltd228
Unknown
3 期
A Study of Azelnidipine Tablets for the treatment of subjects with HypertensioCTRI/2019/07/020126Synokem Pharmaceuticals Ltd